Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.

The inventive transdermal therapeutic systems (TTS) incorporate a timing device, such as an electronic timing device, particularly a thin, electronic timing device. The timing device can be a part of, adhered to, or used in lieu of the TTS backing layer. The device generally includes a pre-programmed or pre-designated timer, an activation and/or reset button to start or reset the timer and an indicator, such as a visual indicator, to alert the patient when the administration time period has lapsed.

Bacteria-responsive core-shell nanofibers and a process for the preparation thereof are described. The nanofibers release of an antibacterial agent in response to the presence of bacteria. The core of the nanofiber comprises a biocompatible polymer together with an antibacterial agent such as a quaternary ammonium compound, for example benzyl dimethyl tetradecyl ammonium chloride (BTAC). Surrounding the core is shell comprised of a bacterially degradable polymer, which is susceptible to break-down by bacterial enzymes such as lipase, or to acidic pH conditions. The shell may comprise, for example, polycaprolactone (PCL) and poly(ethylene succinate) (PES). The nanofibers may be incorporated into wound dressings.

A multilayer flexible film for packaging a transdermal patch product comprising a pharmaceutical active agent comprises: a product-contacting sealing layer comprising a co-polyester having a surface energy of at least 50 dyne/cm.sup.2; and one or more layers above the product-contacting sealing layer. The pharmaceutical active agent may comprise nicotine. An average adhesion force to peel the transdermal patch from the product-contacting sealing layer may be less than 100 g/inch (39.37 g/cm).

Disclosed are PTHrP analogue formulations for transdermal delivery of a therapeutically effective amount of a PTHrP analogue, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.

The invention relates to systems formed from closed liquid-tight packaging and a preferably dimensionally stable aqueous composition which is sealed therein and which, upon activation, releases a liquid phase essentially composed of water in a time-delayed manner. The invention further relates to methods for manufacturing such systems and the use thereof during the production of self-decomposing transdermal therapeutic systems (TTS).

The present invention relates to frigostable compositions suitable for iontophoretic transdermal delivery of a triptan compound. The inventive compositions include a salt of a triptan compound, preferably sumatriptan succinate, a polyamine, a dicarboxylic acid, and water or an aqueous solvent mixture, with the composition being free of monocarboxylic acids. The invention further relates to the use of the composition as an integral component of an iontophoretic patch, preferably as an anodic reservoir of the patch.

Devices, systems, compositions and methods for long term or prolonged transdermal administration of an active agent are provided.

Flexible packages, transdermal drug delivery devices, and methods for fabricating packages are provided. An exemplary flexible package includes a chemical and moisture resistant layer formed from poly(chlorotrifluoroethylene-co-vinylidene fluoride) (“P(CTFE-co-VDF)”) copolymer. Further, the exemplary flexible package includes a substance to be delivered. The substance is applied to or enclosed by the chemical and moisture resistant layer.

The present invention relates to methods for the treatment or prevention of symptoms associated with traumatic brain injury (TBI) and related disorders. The present disclosure provides compositions and methods for preventing, ameliorating, or alleviating neuropsychiatric symptoms and psychiatric disorders associated with TBI and related disorders consisting of administering a matrix-type transdermal patch with a composition consisting of opipramol, excluding any other component such as a pharmaceutical carrier or excipient.